Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel - Summary - MDSpire

Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel

  • By

  • Noopur Raje

  • Kenneth Anderson

  • Hermann Einsele

  • Yvonne Efebera

  • Francesca Gay

  • Sarah P. Hammond

  • Alexander M. Lesokhin

  • Sagar Lonial

  • Heinz Ludwig

  • Philippe Moreau

  • Krina Patel

  • Karthik Ramasamy

  • Maria-Victoria Mateos

  • August 1, 2023

  • 0 min

Share

Objective:

Emphasize the critical need for infection management due to the increasing use of BsAb therapy.

Key Findings:
  • Incorporate specific data points or references to support the findings.
Interpretation:

Expand on the clinical implications of the findings.

Limitations:
  • Clarify how the limited data affects the strength of the recommendations.
Conclusion:

Reiterate the urgency for tailored guidelines based on the findings.

Original Source(s)

Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel

  • by Noopur Raje, Kenneth Anderson, Hermann Einsele, Yvonne Efebera, Francesca Gay, Sarah P. Hammond, Alexander M. Lesokhin, Sagar Lonial, Heinz Ludwig, Philippe Moreau, Krina Patel, Karthik Ramasamy, Maria-Victoria Mateos

  • August 1, 2023

Related Content

Case Study: Non-secretory Multiple Myeloma with Eosinophilia - Diagnostic Hurdles and a Comprehensive Literature Review

Understanding the Role of Regulatory T Cells in the Immune Microenvironment of Multiple Myeloma and Its Clinical Implications

Association of genetic ancestry with outcomes and toxicity of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma